Combined activation of GLP-1, GIP, and GCG systems theoretically provides complementary mechanisms: GLP-1-mediated insulin sensitization and satiety promotion, GIP-mediated enhancement of insulin secretion and adipose lipid buffering, and glucagon-mediated direct hepatic lipid oxidation and energy expenditure augmentation
Contributing factors include underlying mental health disorders, chronic illness, and environmental influences
Eli Lillys Next-Generation GLP-1R Agonist NaperiglipronStructure Revealed | Eli Lilly has disclosed the structure of its next-generation small molecule GLP-1R agonist, naperiglipron (LY3549492)
Dr Adrian points out that their resistant starch content feeds beneficial gut bacteria, which may indirectly support weight control
GLP-1 RAs reduced the risk of progression to ESKD in lupus nephritis patients by lowering pro-inflammatory mediators